Embecta Faces Securities Class Action After 57% Stock Plunge

The lawsuit, Apitz-Grossman v. Embecta Corp., et al., alleges that the medical device manufacturer misled shareholders regarding the market performance of its insulin pen needle portfolio. While company executives previously characterized the product line as resilient and showing positive prescription trends, the complaint asserts that Embecta faced significant competitive pressure and widespread market softness that it failed to disclose to the public.

The stock collapse occurred on May 5, 2026, when Embecta reported revenue figures below guidance, citing share loss from a major customer and a distinct decline in retail channel volume. The resulting market correction saw the stock fall from $9.25 to $3.90 per share in a single session. Alongside the earnings miss, the company slashed its quarterly dividend from $0.15 to $0.01 per share.

Bleichmar Fonti & Auld LLP, the firm representing the class, claims the company violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Shareholders who held positions during the period in question are eligible to participate in the litigation, which is being handled on a contingency fee basis with no upfront costs for investors.